ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

GSK licenses tuberculosis vaccine to Bill & Melinda Gates Medical Research Institute

by Ryan Cross
February 1, 2020 | APPEARED IN VOLUME 98, ISSUE 5

 

09805-buscon15-tb.jpg
Credit: GSK
A researcher at GSK’s vaccine R&D site in Rixensart, Belgium

The Bill & Melinda Gates Medical Research Institute will license an experimental tuberculosis vaccine from GlaxoSmithKline. An existing TB vaccine protects infants and children but not adolescents or adults. The institute plans to further develop the vaccine, M72/AS01E, which recently helped cut TB infections in half in a Phase II clinical trial of HIV-negative adults. The AS01E adjuvant used in the vaccine is also used in GSK’s herpes zoster vaccine, Shingrix.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment